U.S. patent application number 15/429506 was filed with the patent office on 2017-06-01 for method for the treatment of dravet syndrome.
This patent application is currently assigned to THE KATHOLIEKE UNIVERSITEIT LEUVEN. The applicant listed for this patent is THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP. Invention is credited to Berten CEULEMENS, Lieven LAGAE.
Application Number | 20170151259 15/429506 |
Document ID | / |
Family ID | 50729472 |
Filed Date | 2017-06-01 |
United States Patent
Application |
20170151259 |
Kind Code |
A1 |
CEULEMENS; Berten ; et
al. |
June 1, 2017 |
METHOD FOR THE TREATMENT OF DRAVET SYNDROME
Abstract
A method of treating and/or preventing Dravet Syndrome in a
patient such as a patient previously diagnosed with Dravet
Syndrome, by administering an effective dose of fenfluramine or its
pharmaceutically acceptable salt to that patient. Dravet Syndrome
patients are typically children under the age of 18 and are treated
at a preferred dose of less than about 0.5 to about 0.01
mg/kg/day.
Inventors: |
CEULEMENS; Berten; (Leuven,
BE) ; LAGAE; Lieven; (Edegem, BE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
THE KATHOLIEKE UNIVERSITEIT LEUVEN
UNIVERSITY HOSPITAL ANTWERP |
Leuven
Edegem |
|
BE
BE |
|
|
Assignee: |
THE KATHOLIEKE UNIVERSITEIT
LEUVEN
Leuven
BE
UNIVERSITY HOSPITAL ANTWERP
Edegem
BE
|
Family ID: |
50729472 |
Appl. No.: |
15/429506 |
Filed: |
February 10, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15003161 |
Jan 21, 2016 |
9603815 |
|
|
15429506 |
|
|
|
|
13887014 |
May 3, 2013 |
9549909 |
|
|
15003161 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 43/00 20180101;
A61K 45/06 20130101; A61K 31/19 20130101; A61P 25/08 20180101; A61K
31/5513 20130101; C12Q 1/6883 20130101; A61K 31/135 20130101; C12Q
2600/156 20130101; A61K 31/551 20130101; A61K 31/36 20130101; A61K
31/137 20130101; A61K 31/137 20130101; A61K 2300/00 20130101 |
International
Class: |
A61K 31/5513 20060101
A61K031/5513; A61K 31/137 20060101 A61K031/137 |
Claims
1.-20. (canceled)
21. A method of ameliorating seizures in a patient diagnosed with
Dravet syndrome, comprising: administering to the patient an
effective dose of fenfluramine or a pharmaceutically acceptable
salt thereof; and administering to the patient an effective dose of
clobazam or a pharmaceutically acceptable salt thereof; whereby
seizures are ameliorated in the patient.
22. The method of claim 21, wherein the fenfluramine or
pharmaceutically acceptable salt thereof is administered in a dose
of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient.
23. A method of treating a patient diagnosed with Dravet syndrome
and exhibiting a mutation in a gene, comprising: administering to
the patient an effective dose of fenfluramine or a pharmaceutically
acceptable salt thereof; and administering to the patient an
effective dose of clobazam or a pharmaceutically acceptable salt
thereof; whereby seizures are ameliorated in the patient exhibiting
the mutation.
24. The method of claim 23, wherein the mutation is selected from
the group consisting of SCN1A, SCN1B, SCN2A, SCN3A, SCN9A, GABRG2,
GABRD and PCDH19.
25. The method of claim 24, wherein the fenfluramine or
pharmaceutically acceptable salt thereof is administered in a dose
of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient.
26. A method, comprising: determining a patient has a mutation in a
gene which mutation is associated with Dravet syndrome;
administering to the patient determined to have the mutation: (a)
an effective dose of fenfluramine or a pharmaceutically acceptable
salt thereof; and (b) an effective dose of clobazam or a
pharmaceutically acceptable salt thereof; whereby seizures are
ameliorated in the patient exhibiting the mutation.
27. The method as claimed in claim 26, wherein the mutation is
selected from the group consisting of SCN1A, SCN1B, SCN2A, SCN3A,
SCN9A, GABRG2, GABRD and PCDH19
28. The method of claim 27, wherein the fenfluramine or
pharmaceutically acceptable salt thereof is administered in a dose
of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient.
29. A method of stimulating 5-HT receptors in the brain of a
patient diagnosed with Dravet syndrome, comprising: administering
to the patient an effective dose of fenfluramine or a
pharmaceutically acceptable salt thereof; and administering to the
patient an effective dose of clobazam or a pharmaceutically
acceptable salt thereof; whereby 5-HT receptors are stimulated and
wherein the 5-HT receptor is in a family of receptors selected from
the group consisting of 5-HT1, 5- HT2, 5-HT3, 5-HT4, 5-HTS, 5-HT6,
and 5-HT7.
30. The method of claim 29, wherein the 5-HT receptor is in the
5-HT1 receptor family and is selected from the group consisting of
5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, 5-HT1E, 5-HT1F.
31. The method of claim 29, wherein the 5-HT receptor is in the
5-HT2 receptor family and is selected from the group consisting of
5-HT2A, 5-HT2B, 5-HT2C.
32. The method of claim 29, wherein the 5-HT receptor is in the
5-HT3 receptor family and is selected from the group consisting of
5-HT3A, 5-HT3B.
33. The method of claim 29, wherein the fenfluramine or
pharmaceutically acceptable salt thereof is administered in a dose
of 0.5 mg/kg/day to 0.01 mg/kg/day to the patient.
Description
BACKGROUND ART
[0001] This invention relates to the treatment of Dravet Syndrome
using an amphetamine derivative, specifically fenfluramine.
[0002] Fenfluramine, i.e. 3-trifluoromethyl-N-ethylamphetamine is
an amphetamine derivative having the structure:
##STR00001##
Fenfluramine was first marketed in the US in 1973 and had been
administered in combination with phentermine to prevent and treat
obesity. However, in 1997, it was withdrawn from the US market as
its use was associated with the onset of cardiac fibrosis and
pulmonary hypertension. Subsequently, the drug was withdrawn from
sale globally and is no longer indicated for use in any therapeutic
area.
[0003] Despite the health concerns surrounding fenfluramine,
attempts have been made to identify further therapeutic uses for
that product. Aicardi and Gastaut (New England Journal of Medicine
(1985), 313:1419 and Archives of Neurology (1988) 45:923-925)
reported four cases of self-induced photosensitive seizures that
responded to treatment with fenfluramine.
[0004] Clemens, in Epilepsy Research (1988) 2:340-343 reported a
study on a boy suffering pattern sensitivity-induced seizures that
were resistant to anticonvulsive treatment. Fenfluramine reportedly
successfully terminated these self-induced seizures and the author
concluded that this was because fenfluramine blocked the
photosensitive triggering mechanism.
[0005] In Neuropaediatrics, (1996); 27(4):171-173, Boel and Casaer
reported on a study on the effects of fenfluramine on children with
refractory epilepsy. They concluded that when fenfluramine was
administered at a dose of 0.5 to 1 mg/kg/day, this resulted in a
reduction in the number of seizures experienced by the
patients.
[0006] In a letter to Epilepsia, published in that journal
(Epilepsia, 43(2):205-206, 2002), Boel and Casaer commented that
fenfluramine appeared to be of therapeutic benefit in patients with
intractable epilepsy.
[0007] Epilepsy is a condition of the brain marked by a
susceptibility to recurrent seizures. There are numerous causes of
epilepsy including, but not limited to birth trauma, perinatal
infection, anoxia, infectious diseases, ingestion of toxins,
tumours of the brain, inherited disorders or degenerative disease,
head injury or trauma, metabolic disorders, cerebrovascular
accident and alcohol withdrawal.
[0008] There are a large number of subtypes of epilepsy that have
been characterised. For example, the following list of conditions
are set out in Meritt's Neurology (12th Edition):
I. Idiopathic epilepsy syndromes (focal or generalised)
[0009] A. Benign neonatal convulsions [0010] 1. Familial [0011] 2.
Nonfamilial
[0012] B. Benign childhood epilepsy [0013] 1. With
central-midtemporal spikes [0014] 2. With occipital spikes
[0015] C. Childhood/juvenile absence epilepsy
[0016] D. Juvenile myoclonic epilepsy (including generalised
tonic-clonic seizures on awakening)
[0017] E. Idiopathic epilepsy, otherwise unspecified
II. Symptomatic epilepsy syndromes (focal or generalised)
[0018] A. West syndrome (infantile spasms)
[0019] B. Lennox-Gastaut syndrome
[0020] C. Early myoclonic encephalopathy
[0021] D. Epilepsia partialis continua
1. Rasmussen syndrome (encephalitic form) 2. Restricted form
[0022] E. Acquired epileptic aphasia (Landau-Kleffner syndrome)
[0023] F. Temporal lobe epilepsy
[0024] G. Frontal lobe epilepsy
[0025] H. Posttraumatic epilepsy
[0026] I. Other symptomatic epilepsy, focal or generalised, not
specified
III. Other epilepsy syndromes of uncertain or mixed
classification
[0027] A. Neonatal seizures
[0028] B. Febrile seizures
[0029] C. Reflex epilepsy
[0030] D. Other unspecified
[0031] As can be seen from, for example, Part III of that list,
there are still subtypes of epilepsy that have not yet been fully
characterized and thus, the list is far from complete.
[0032] Those skilled in the art will recognize that these subtypes
of epilepsy are triggered by different stimuli, are controlled by
different biological pathways and have different causes, whether
genetic or environmental. In other words, the skilled artisan will
recognize that teachings relating to one epileptic subtype are not
necessarily be applicable to other subtypes. This can include
recognition that different epilepsy subtypes respond differently to
different anticonvulsant drugs.
[0033] Dravet Syndrome is a rare and catastrophic form of
intractable epilepsy that begins in infancy. Initially, the patient
experiences prolonged seizures. In their second year, additional
types of seizure begin to occur and this typically coincides with a
developmental decline, possibly due to repeated cerebral hypoxia.
This leads to poor development of language and motor skills.
[0034] Children with Dravet Syndrome are likely to experience
multiple seizures per day. Epileptic seizures are far more likely
to result in death in sufferers of Dravet Syndrome; approximately
10 to 15% of patients diagnosed with Dravet Syndrome die in
childhood, particularly between two and four years of age.
Additionally, patients are at risk of numerous associated
conditions including orthopedic developmental issues, impaired
growth and chronic infections.
[0035] Of particular concern, children with Dravet Syndrome are
particularly susceptible to episodes of Status Epilepicus. This
severe and intractable condition is categorized as a medical
emergency requiring immediate medical intervention, typically
involving hosptialisation. Status Epilepticus can be fatal. It can
also be associated with cerebral hypoxia, possibly leading to
damage to brain tissue. Frequent hospitalizations of children with
Dravet Syndrome are clearly distressing, not only to the patient
but also to family and carers.
[0036] The cost of care for Dravet Syndrome patients is also high
as the affected children require constant supervision and many
require institutionalisation as they reach teenage years.
[0037] At present, although a number of anticonvulsant therapies
can be employed to reduce the instance of seizures in patients with
Dravet Syndrome, the results obtained with such therapies are
typically poor and those therapies only effect partial cessation of
seizures at best.
[0038] Seizures associated with Dravet Syndrome are typically
resistant to conventional treatments. Further, many anticonvulsants
such as clobazam and clonazepam have undesirable side effects,
which are particularly acute in pediatric patients.
[0039] Stiripentol is approved in Europe but not in the US for the
treatment of Dravet Syndrome. It does not exhibit an anticonvulsant
activity in its own right; it acts by inhibiting the metabolism of
other anticonvulsants thereby prolonging their activity. However,
concerns remain regarding the use of stiripentol due to its
inhibitory effect on hepatic cytochrome P450. Further, the
interactions of stiripentol with a large number of drugs means that
combination therapy (which is typically required for patients with
Dravet Syndrome) is problematic.
[0040] There is accordingly a need to provide an improved method
for treating or preventing Dravet Syndrome and/or for treating,
preventing and/or ameliorating seizures experienced by sufferers of
Dravet Syndrome.
BRIEF SUMMARY OF THE INVENTION
[0041] According to a first aspect of the present invention, there
is provided a method of treating and/or preventing Dravet Syndrome
in a patient comprising administering an effective dose of
fenfluramine to that patient.
[0042] According to a further aspect of the present invention,
there is provided a method of treating, preventing and/or
ameliorating seizures in a patient diagnosed with Dravet Syndrome
comprising administering an effective dose of fenfluramine to that
patient.
[0043] According to a further aspect of the present invention,
there is provided a method of treating a patient that exhibits a
mutation in one or more of a gene selected from the group
consisting of SCN1A, SCN1B, SCN2A, SCN3A, SCN9A, GABRG2, GABRD and
PCDH19 by by administering to that patient an effective dose of
fenfluramine.
[0044] A still further aspect of this invention contemplates a
method for stimulating one or more 5-HT receptors in the brain of a
patient by administering an effective dose of fenfluramine or a
pharmaceutically acceptable salt thereof to that patient.
Illustrative one or more 5-HT receptors are selected from the group
consisting of one or more of 5-HT.sub.1, 5-HT.sub.1A, 5-HT.sub.1B,
5-HT.sub.1C, 5-HT.sub.1D, 5-HT.sub.1E, 5-HT.sub.1F, 5-HT.sub.2,
5-HT.sub.2A, 5-HT.sub.2B, 5-HT.sub.2C, 5-HT.sub.3, 5-HT.sub.4,
5-HT.sub.5, 5-HT.sub.5A, 5-HT.sub.5B 5-HT.sub.6, and
5-HT.sub.7.
[0045] Yet another aspect of the invention contemplates
coadministration of an effective dose of one or more co-therapeutic
agents with the fenfluramine.
DETAILED DESCRIPTION OF THE INVENTION
[0046] After many years of extensive research, it has unexpectedly
been found that fenfluramine can be used to treat, or at least
minimize the effects of Dravet Syndrome. This is confirmed by the
results presented herein, and also in the article by Ceulemans et
al., Epilepsia (2012) 53(7):1131-1139, the contents of which are
incorporated herein.
[0047] For the avoidance of doubt, the term "prevention" of
seizures means the total or partial prevention (inhibition) of
seizures. Ideally, the methods of the present invention result in a
total prevention of seizures; indeed, this ideal has been achieved
in a number of patients treated by the inventors. However, the
invention also encompasses methods in which the instances of
seizures are decreased by at least 50%, at least 60%, at least 70%,
at least 80% or at least 90%.
[0048] It is known that patients with Dravet Syndrome commonly
experience photosensitive or induced seizures. From teachings in
the prior art, e.g. Aicardi and Gastaut (1988) and Boel and Casaer
(1996)--both discussed above, it might have been expected that
fenfluramine would reduce photosensitive or induced seizures.
Importantly, however, it has surprisingly been found that all types
of seizures exhibited by patients with Dravet Syndrome, that is
seizures in addition to and other than those that are
photosensitive or induced can be suppressed by treatment in
accordance with a method of the present invention.
[0049] Thus, in context of the present invention, the term
"seizure" is used to not only encompass photosensitive or induced
seizures, but some or all of the other types of seizures
experienced by epileptics, including but not limited to Status
Epilepticus.
[0050] There are a number of genetic mutations that are indicative
of Dravet Syndrome. Mutations in the SCN1A (such as partial or
total deletion mutations, truncating mutations and/or missense
mutations e.g. in the voltage or pore regions S4 to S6), SCN1B
(such as the region encoding the sodium channel .beta.1 subunit),
SCN2A, SCN3A, SCN9A, GABRG2 (such as the region encoding the
.gamma.2 subunit), GABRD (such as the region encoding the 5
subunit) and/or PCDH19 genes have been linked to Dravet
Syndrome.
[0051] Thus, according to a further aspect of the present
invention, there is provided a method of treating a patient that
exhibits a mutation in one, some or all of the above genes by
administering to that patient an effective dose of fenfluramine. In
certain embodiments of this aspect of the invention, the patient
has been diagnosed with Dravet Syndrome.
[0052] Fenfluramine has been known to inhibit serotonin reuptake
and to trigger the release of serotonin in the brain due to
disruption of its vesicular storage. However, until the present
invention was made, it was not known that fenfluramine's mechanism
of action made it suitable for the treatment of Dravet
Syndrome.
[0053] Thus, according to a still further aspect of the present
invention, there is provided a method of stimulating one or more
5-HT receptors in the brain of a patient by administering an
effective dose of fenfluramine to said patient, said one or more
5-HT receptors being selected from one or more of 5-HT.sub.1,
5-HT.sub.1A, 5-HT.sub.B, 5-HT.sub.1D, 5-HT.sub.1E, 5-HT.sub.2,
5-HT.sub.2A, 5-HT.sub.2B, 5-HT.sub.2C, 5-HT.sub.3, 5-HT.sub.4,
5-HT.sub.5, 5-HT.sub.5A, 5-HT.sub.5B 5-HT.sub.6, and 5-HT.sub.7
amongst others. In certain embodiments of this aspect of the
invention, the patient has been diagnosed with Dravet Syndrome.
[0054] In embodiments of the invention, any effective dose of
fenfluramine can be employed. However, surprisingly low doses of
fenfluramine have been found by the inventors to be efficacious,
particularly for inhibiting or eliminating seizures in Dravet
Syndrome patients. Thus, in preferred embodiments of the invention,
a daily dose of less than about 0.5 mg/kg/day, about 0.45
mg/kg/day, about 0.4 mg/kg/day, about 0.3 mg/kg/day, about 0.25
mg/kg/day or about 0.2 mg/kg/day to about 0.1 mg/kg/day, about 0.05
mg/kg/day, or about 0.01 mg/kg/day is employed. Put differently, a
preferred dose is less than about 0.5 to about 0.01 mg/kg/day. Such
a dose is less than the daily dose of fenfluramine suggested for
administration to achieve weight loss.
[0055] The dose of fenfluramine administered in the methods of the
present invention can be formulated in any pharmaceutically
acceptable dosage form including, but not limited to oral dosage
forms such as tablets including orally disintegrating tablets,
capsules, lozenges, oral solutions or syrups, oral emulsions, oral
gels, oral films, buccal liquids, powder e.g. for suspension, and
the like; injectable dosage forms; transdermal dosage forms such as
transdermal patches, ointments, creams; inhaled dosage forms;
and/or nasally, rectally, vaginally administered dosage forms. Such
dosage forms can be formulated for once a day administration, or
for multiple daily administrations (e.g. 2, 3 or 4 times a day
administration).
[0056] The dosage form of fenfluramine employed in the methods of
the present invention can be prepared by combining fenfluramine
with one or more pharmaceutically acceptable diluents, carriers,
adjuvants, and the like in a manner known to those skilled in the
art of pharmaceutical formulation.
[0057] In a method of the present invention, fenfluramine can be
employed as a monotherapy in the treatment of Dravet Syndrome.
Alternatively, fenfluramine can be coadministered simultaneously,
sequentially or separately with one or more co-therapeutic agents,
such as anticonvulsants. Preferred co-therapeutic agents can be
selected from the group consisting of carbamazepine, ethosuximide,
fosphenytoin, lamotrigine, levetiracetam, phenobarbitol, progabide,
topiramate, stiripentol, valproic acid, valproate, verapamil, and
benzodiazepines such as clobazam, clonazepam, diazepam, ethyl
loflazepate, lorazepam, midazolam. Use of a pharmaceutically
acceptable salt of a co-therapeutic agent is also contemplated.
Fenfluramine can be administered in the form of the free base, or
in the form of a pharmaceutically acceptable salt, for example
selected from the group consisting of hydrochloride, hydrobromide,
hydroiodide, maleate, sulphate, tartrate, acetate, citrate,
tosylate, succinate, mesylate and besylate. Further illustrative
pharmaceutically acceptable salts can be found in Berge et al., J.
Pharm Sci. (1977) 68(1):1-19.
[0058] Fenfluramine for use in the methods of the present invention
may be produced according to any pharmaceutically acceptable
process known to those skilled in the art. Examples of processes
for synthesizing fenfluramine are provided in the following
documents: GB1413070, GB1413078 and EP441160.
[0059] The dose of fenfluramine to be used in a method of the
present invention can be provided in the form of a kit, including
instructions for using the dose in one or more of the methods of
the present invention. In certain embodiments, the kit can
additionally comprise a dosage form comprising one or more
co-therapeutic agents.
[0060] A method of the present invention can be practiced on any
appropriately diagnosed patient. In a typical embodiment of the
present invention, the patient is aged about 18 or less, about 16
or less, about 14 or less, about 12 or less, about 10 or less,
about 8 or less, about 6 or less or about 4 or less to about 0
months or more, about 1 month or more, about 2 months or more,
about 4 months or more, about 6 months or more or about 1 year or
more. Thus, the diagnosed patient is typically about one month old
to about 18 years old when treated.
[0061] The invention is further illustrated in the following
Comparative Example.
Comparative Example
[0062] The results of two pivotal studies (conducted in France and
Italy) that led to approval of stiripentol in the European Union
are provided below. In the first table, the number of test subjects
who became seizure-free upon co-administration of stiripentol and
either valproate or clobazam vs a placebo or two months is
provided. In the second table, the number of subjects who exhibited
a >50% reduction in the number of seizures following
administration of stiripentol and either valproate or clobazam vs a
placebo or two months is provided.
TABLE-US-00001 TABLE 1 Seizure Free Patients (Treated with
Stiripentol and either Valproate or Clobazam vs Placebo) Seizure
Free Patients Stiripentol Placebo STICLO-France 9/20 (45%) 0/16
(0%) STICLO-Italy 3/11 (27%) 0/9 (0%) Combined 12/31 (38.7%) 0/25
(0%)
TABLE-US-00002 TABLE 2 Responders->50% Reduction in the Number
of Seizures (Treated with Stiripentol and either Valproate or
Clobazam vs Placebo) Responders Stiripentol Placebo STICLO-France
15/21 (71.4%) 1/20 (5%) STICLO-Italy 8/12 (66.7%) 1/11 (9.1%)
Combined 23/33 (69.7%) 2/31 (6.5%)
[0063] The following table provides results based on the data
presented in Ceulemans et al., Epilepsia (2012) 53(7):1131-1139.
Patients were administered an average daily dose of fenfluramine of
0.34 mg/kg/day for between 1 and 22 years.
TABLE-US-00003 TABLE 3 Seizure Free Patients and Responders
(Treated with Fenfluramine and Valproate) Fenfluramine Seizure-free
Patients >50% Reduction in Seizures 8/12 (66%) 9/12 (75%)
As can be seen from the foregoing data, long-term fenfluramine
treatment advantageously resulted in a seizure-free condition in
66.6% of test subjects, compared to 38.7% for stiripentol.
[0064] Additionally, long-term fenfluramine treatment
advantageously resulted in a slightly improved reduction in
seizures (75%) as compared to the reduction in seizures in patients
treated with stiripentol for two months (69.7%).
[0065] These results confirm that fenfluramine provides long term
elimination/reduction in seizures to a greater extent than observed
with short term administration of the currently approved therapy
(in the EU), stiripentol.
[0066] These results were achieved, in the vast number of cases,
using significantly lower doses of fenfluramine than those proposed
previously in the treatment of various conditions typified by
seizures. Additionally and surprisingly, fenfluramine effectively
reduced the incidence of all types of seizures and not only
photosensitive or self-induced seizures.
[0067] The subjects treated with fenfluramine were monitored using
echocardiography for possible heart valve defects. No clinically
relevant defects were identified.
[0068] Each of the patents, patent applications and articles cited
herein is incorporated by reference. The use of the article "a" or
"an" is intended to include one or more.
[0069] The foregoing description and the examples are intended as
illustrative and are not to be taken as limiting. Still other
variations within the spirit and scope of this invention are
possible and will readily present themselves to those skilled in
the art.
* * * * *